Drug-induced lung injury.

Semin Roentgenol

Department of Radiology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Published: January 2002

Lung injury is an increasing cause of morbidity and mortality in patients treated with cytotoxic and noncytotoxic drugs. Prompt diagnosis is important because early drug-induced lung injury will often regress with the cessation of therapy. Diagnosis requires a high index of suspicion because infection, radiation pneumonitis, and recurrence of the underlying disease can manifest clinically and radiologically in a similar manner. Because the lungs have only a limited number of histopathologic responses to injury, including pulmonary edema/diffuse alveolar damage, NSIP, BOOP, EP, and pulmonary hemorrhage, knowledge of these manifestations and the corresponding radiologic manifestations can often be useful in suggesting a diagnosis of drug-induced lung injury. An understanding of the drugs most commonly associated with lung injury can also facilitate diagnosis.

Download full-text PDF

Source
http://dx.doi.org/10.1053/sroe.2002.0000DOI Listing

Publication Analysis

Top Keywords

lung injury
20
drug-induced lung
12
injury
6
lung
4
injury lung
4
injury increasing
4
increasing morbidity
4
morbidity mortality
4
mortality patients
4
patients treated
4

Similar Publications

[Clinical characteristics and prognosis of type 1 infratentorial superficial siderosis].

Zhonghua Yi Xue Za Zhi

February 2025

Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China.

A total of 7 patients with type 1 infratentorial superficial siderosis(iSS-1)in Memory Clinic at Huashan Hospital, Fudan University from March 2019 to March 2023 were respectively collected to analyze the clinical characteristics and treatment, and followed up for 12 months. There were 7 patients, 2 males and 5 females, aged 56 (49-60) years. The 4 patients who underwent cognitive assessment had varying degree of cognitive impairment, with 2 patients exhibiting severe executive function impairment.

View Article and Find Full Text PDF

Acute lung injury (ALI) is a clinically common disease with high mortality, characterized by tissue damage caused by excessive activation of inflammation. TRIM7 is an E3 ligase that plays an important role in regulating viral infection, tumor progression and innate immune response. But its function in ALI is unclear.

View Article and Find Full Text PDF

Background: The benefit of mechanical circulatory support (MCS) with Impella (Abiomed, Inc, Danvers, MA) for patients undergoing non-emergent, high-risk percutaneous coronary intervention (HR-PCI) is unclear and currently the subject of a large randomized clinical trial (RCT), PROTECT IV. While contemporary registry data from PROTECT III demonstrated improvement of outcomes with Impella when compared with historical data (PROTECT II), there is lack of direct comparison to the HR-PCI cohort that did not receive Impella support.

Methods: We retrospectively identified patients from our institution meeting PROTECT III inclusion criteria (left ventricular ejection fraction [LVEF] <35% with unprotected left main or last remaining vessel or LVEF <30% undergoing multivessel PCI), and compared this group (NonIMP) to the published outcomes data from the PROTECT III registry (IMP).

View Article and Find Full Text PDF

Objective: We aimed to understand the potential therapeutic and anti-inflammatory effects of the phosphodiesterase-4 (PDE4) inhibitor roflumilast in models of pulmonary infection caused by betacoronaviruses.

Methods: Mice were infected intranasally with murine hepatitis virus (MHV-3) or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Roflumilast was given to MHV-3-infected mice therapeutically at doses of 1 mg/kg or 10 mg/kg, or prophylactically at 10 mg/kg.

View Article and Find Full Text PDF

Background: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!